Clinical Trial Finder

DISEASE CHARACTERISTICS:

• - Histologically confirmed* malignant solid tumor, including CNS tumors, at original diagnosis or relapse.

• - Recurrent or refractory disease NOTE: *Histologic confirmation not required for intrinsic brain stem or optic pathway tumors.

• - Measurable or evaluable disease, defined by 1 of the following criteria: - Any unidimensionally measurable lesion ≥ 10 mm by standard MRI or CT scan for either solid or CNS tumors.

• - At least 1 nonmeasurable lesion that is evaluable by nuclear medicine, immunocytochemistry, tumor markers, cerebrospinal fluid cytology, or other reliable measures.

• - No known curative therapy exists.

• - No documented tumor involvement in the bone marrow.

PATIENT CHARACTERISTICS: Age.

• - 2 to 21.

Performance status*

• - Lansky 50-100% (for patients ≤ 10 years of age) - Karnofsky 50-100% (for patients > 10 years of age) Life expectancy.

• - Not specified.

Hematopoietic.

• - Absolute neutrophil count ≥ 1,000/mm^3.

• - Platelet count ≥ 100,000/mm^3 (transfusion independent) - Hemoglobin ≥ 8.0 g/dL (transfusions allowed) Hepatic.

• - Bilirubin ≤ 1.5 times upper limit of normal (ULN) - ALT ≤ 110 (ULN for this study is 45 U/L) - Albumin ≥ 2 g/dL.

Renal.

• - Creatinine clearance or radioisotope glomerular filtration rate ≥ 70 mL/min OR.

• - Creatinine based on age as follows: - No greater than 0.8 mg/dL (for patients ≤ 5 years of age) - No greater than 1.0 mg/dL (for patients 6 to 10 years of age) - No greater than 1.2 mg/dL (for patients 11 to 15 years of age) - No greater than 1.5 mg/dL (for patients over 15 years of age) Other.

• - Not pregnant or nursing.

• - Negative pregnancy test.

• - Fertile patients must use effective contraception.

• - Neurologic deficits in patients with CNS tumors must be stable for ≥ 1 week before study entry.

• - No uncontrolled infection.

• - No known urea cycle disorders or other metabolic disorders.

• - No other condition that would preclude study compliance.

PRIOR CONCURRENT THERAPY: Biologic therapy.

• - Recovered from prior immunotherapy.

• - At least 7 days since prior hematopoietic growth factors that support platelet or WBC number or function.

• - At least 7 days since prior antineoplastic biologic agents.

• - At least 3 months since prior stem cell transplantation or rescue without total body irradiation.

• - No evidence of active graft vs.host disease.

• - No other concurrent anticancer biologic therapy or immunotherapy.

Chemotherapy.

• - More than 3 weeks since prior myelosuppressive chemotherapy (6 weeks for nitrosoureas) and recovered.

• - No other concurrent anticancer chemotherapy.

Endocrine therapy.

• - Patients with CNS tumors must be on a stable or decreasing dose of dexamethasone for the past 7 days.

Radiotherapy.

• - See Biologic therapy.

• - Recovered from prior radiotherapy.

• - At least 6 months since prior total body irradiation, craniospinal radiotherapy, or radiotherapy to ≥ 50% of the pelvis.

• - At least 6 weeks since other prior substantial bone marrow radiotherapy.

• - At least 2 weeks since prior local palliative small port radiotherapy.

• - No concurrent anticancer radiotherapy.

Surgery.

• - Not specified.

Other.

• - No other concurrent investigational agents.

• - No other concurrent anticancer agents.

• - No other concurrent anticonvulsants.

- Patients receiving valproic acid (VPA) before study entry must have a total trough VPA concentration < 100 mcg/mL within the past 7 days

OBJECTIVES: Primary.

• - Determine the toxic effects of valproic acid (VPA) administered at doses required to maintain serum trough VPA concentrations of 100-150 mcg/mL or 150-200 mcg/mL in young patients with recurrent or refractory solid tumors or CNS tumors.

Secondary.

• - Determine the steady-state serum trough concentration of free and total VPA at the targeted total trough VPA concentration in these patients.

• - Determine the steady state histone acetylation status of peripheral blood monocytes at the targeted trough VPA concentration in these patients.

• - Determine the pharmacokinetic profile of this drug in these patients.

• - Correlate histone acetylation with free or total trough VPA concentration in these patients.

• - Determine, preliminarily, the antitumor activity of this drug in these patients.

OUTLINE: This is a dose-escalation, multicenter study. For course 1, patients receive escalating doses of oral valproic acid (VPA) twice daily until a target serum trough VPA concentration range is maintained for 28 days. Patients who achieve the target serum trough VPA concentration range receive subsequent courses of oral VPA twice daily (at the dose found to maintain the target serum trough VPA concentration range) on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. The first cohort of 6 patients receives VPA to achieve an initial target trough serum VPA concentration. If fewer than 2 of 6 patients in the first cohort experience dose-limiting toxicity (DLT), then a second cohort of 6 patients receives VPA to achieve the next higher target trough serum VPA concentration. If fewer than 2 patients from the second cohort experience DTL, then 6 additional patients are enrolled in this cohort to better define pharmacokinetics and DLT at this VPA concentration range. After completion of study treatment, patients are followed annually. PROJECTED ACCRUAL: A total of 12-18 patients will be accrued for this study.

Arms

Experimental: Treatment 1

VPA Target Trough Concentration 75-100 mcg/mL, week 1 VPA dose: 15 mg/kg/day, divided tid

Experimental: Treatment 10

VPA Target Trough Concentration 100-150 mcg/mL, week 1 VPA dose: 15 mg/kg/day, divided tid

Experimental: Treatment 20

VPA Target Trough Concentration 150-200 mcg/mL

Interventions

Drug: - valproic acid